A nurse fills a syringe with Moderna Covid-19 vaccine.Fred Tanneau | Afp | Getty ImagesModerna on Tuesday mentioned a brand new model of its Covid vaccine triggered a stronger immune response towards the virus than its present shot in a late-stage trial. The outcomes come as Moderna competes with rival Pfizer for extra share of the Covid vaccine market and tries to diversify its income streams after the world noticed a plunge in demand for Covid merchandise final 12 months. Moderna’s present Covid vaccine, often known as Spikevax, is its solely commercially obtainable product. The biotech firm’s new shot may supply an extended shelf life and simpler storage than its Covid vaccine. Moderna’s new shot is designed to last more when refrigerated. That would make the jab simpler to distribute world wide, particularly in creating international locations that won’t have freezer capabilities. The corporate will accomplish that by shortening the size of the mRNA strand within the vaccine, Moderna beforehand advised CNBC. The brand new shot can also be a “crucial part” of Moderna’s mixture vaccine focusing on Covid and the flu, the corporate mentioned in a launch. Each Moderna and Pfizer have mentioned that the comfort of receiving safety towards two viruses directly may encourage extra folks to get vaccinated towards Covid. The section three trial adopted roughly 11,400 folks ages 12 and older within the U.S., U.Ok. and Canada. Moderna’s new shot particularly triggered the next immune response towards omicron subvariants BA.4 and BA.5 and the unique pressure of the virus than the corporate’s bivalent vaccine focusing on these variants. The advantages had been “most acutely” seen in sufferers over the age of 65, who’re additionally at highest danger of extreme sickness from Covid. Extra CNBC well being coverageThe commonest unwanted side effects had been injection web site ache, headache, fatigue, muscle aches and chills, in keeping with the corporate’s launch. Total, Moderna mentioned the security profile is much like the authorised vaccine Spikevax. An in depth evaluation of the late-stage trial outcomes will likely be introduced at Moderna’s vaccines occasion for traders Wednesday. On the occasion, the corporate will spotlight different components of its pipeline. Moderna is working to develop photographs towards the flu, most cancers and different illness. The corporate’s shot towards respiratory syncytial virus is predicted to win Meals and Drug Administration approval in Could.Moderna has additionally mentioned it plans to launch as much as 15 merchandise within the subsequent 5 years — a aim it first outlined throughout its annual analysis and growth day in September.Don’t miss these tales from CNBC PRO: